Orotracheal treprostinil administration attenuates bleomycin‐induced lung injury, vascular remodeling, and fibrosis in mice
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Pulmonary fibrosis is a progressive disease characterized by disruption of lung architecture and deregulation of the pulmonary function. Prostacyclin, a metabolite of arachidonic acid, is a potential disease mediator since it exerts anti‐inflammatory and anti‐fibrotic actions. We investigated the effect of treprostinil, a prostacyclin analogue, in bleomycin‐induced experimental pulmonary fibrosis. Bleomycin sulfate or saline was administrated intratracheally to mice ( n = 9–10/group) at day 0. Orotracheal aspiration of treprostinil or vehicle was administered daily and started 24 h prior to bleomycin challenge. Evaluation of lung pathology was performed in tissue samples and bronchoalveolar lavage fluid collected 7, 14 and 21 days after bleomycin exposure. Lung injury was achieved due to bleomycin exposure at all time points as indicated by impaired lung mechanics, pathologic lung architecture (from day 14), and cellular and protein accumulation in the alveolar space accompanied by a minor decrease in lung tissue VE‐cadherin at day 14. Treprostinil preserved lung mechanics, and reduced lung inflammation, fibrosis, and vascular remodeling (day 21); reduced cellularity and protein content of bronchoalveolar lavage fluid were additionally observed with no significant effect on VE‐cadherin expression. Bleomycin‐induced collagen deposition was attenuated by treprostinil from day 14, while treprostinil involvement in regulating inflammatory processes appears mediated by NF‐κB signaling. Overall, prophylactic administration of treprostinil, a stable prostacyclin analogue, maintained lung function, and prevented bleomycin‐induced lung injury, and fibrosis, as well as vascular remodeling, a hallmark of pulmonary hypertension. This suggests potential therapeutic efficacy of treprostinil in pulmonary fibrosis and possibly in pulmonary hypertension related to chronic lung diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A phase 1 trial (ACTRN12619001239156) was completed and demonstrated treatment-related GI adverse events, but no serious adverse events were reported [125].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [125]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 1×
“Several multicenter clinical trials have been conducted for IPF, but only two drugs (pirfenidone and nintedanib) were proved to be effective as disease-modifying therapies.(5) However, for a number of patients the only effective treatment will still be lung transplantation.”
BackgroundHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441 · cited 1×
“Treprostinil is a prostanoid analogue that has been introduced as a specific treatment for pulmonary arterial hypertension following a randomized control trial that demonstrated its safety and efficacy.(23) Since then it has been a valuable asset, under different formulations, in the treatment of PAH patients.”
BackgroundStandardized Quantification of Pulmonary Fibrosis in Histological Samples
Hübner, R.-H., Gitter, W., Eddine El Mokhtari, N., Mathiak, M., Both, M., Bolte, H., Freitag-Wolf, S., & Bewig, B. (2008) · BioTechniques · doi:10.2144/000112729 · Cited by 817 · cited 2×
“Aschroft test was used for the quantification of fibrotic injury in the lung according to Hubner et al.(21)”
MethodPulmonary hypertension in chronic lung disease and hypoxia
Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01914-2018 · Cited by 757
Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis
Pardo, A., Gibson, K., Cisneros, J., Richards, T. J., Yang, Y., Becerril, C., Yousem, S., Herrera, I., Ruiz, V., Selman, M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020251 · Cited by 489 · cited 1×
“OPN is suggested to have a profibrotic effect in disease development(50) and to induce fibroblast growth and migration.(47) Treprostinil administration attenuated OPN increase in our experimental setting.”
BackgroundKaminski, N., Allard, J. D., Pittet, J. F., Zuo, F., Griffiths, M. J. D., Morris, D., Huang, X., Sheppard, D., & Heller, R. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1778 · Cited by 417 · cited 1×
“We observed increased levels of OPN in mouse BALF due to BLM exposure and our finding is consistent with previous studies on experimental lung fibrosis.(49) OPN is suggested to have a profibrotic effect in disease development(50) and to induce fibroblast growth and migration.”
ResultFukuhara, S., Sakurai, A., Sano, H., Yamagishi, A., Somekawa, S., Takakura, N., Saito, Y., Kangawa, K., & Mochizuki, N. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.136-146.2005 · Cited by 409
Wilborn, J., Crofford, L. J., Burdick, M. D., Kunkel, S. L., Strieter, R. M., & Peters-Golden, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117866 · Cited by 392
Idiopathic Pulmonary Fibrosis: Prognostic Value of Changes in Physiology and Six-Minute-Walk Test
Flaherty, K. R., Andrei, A.-C., Murray, S., Fraley, C., Colby, T. V., Travis, W. D., Lama, V., Kazerooni, E. A., Gross, B. H., Toews, G. B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-488oc · Cited by 380
Modeling pulmonary fibrosis with bleomycin
Mouratis, M. A., & Aidinis, V. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349ac2b · Cited by 311 · cited 1×
“The animal model most widely used to resemble the human disease is the bleomycin (BLM) mouse model.(6) Previous studies have revealed possible target molecules participating in IPF pathogenesis.”
MethodSelf-citationPeriostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell
Kudo, A. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0784-5 · Cited by 299
Birukova, A. A., Zagranichnaya, T., Fu, P., Alekseeva, E., Chen, W., Jacobson, J. R., & Birukov, K. G. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.03.036 · Cited by 285
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis
Naik, P. K., Bozyk, P. D., Bentley, J. K., Popova, A. P., Birch, C. M., Wilke, C. A., Fry, C. D., White, E. S., Sisson, T. H., Tayob, N., et al. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00139.2012 · Cited by 260 · cited 1×
“Serum periostin levels are elevated in IPF patients and are correlated with disease progression.(53,54) In accordance with the above, we observed an increase of periostin in BALF of our BLM-challenged mice, a phenomenon attenuated by treprostinil administration.”
ResultScott, M. K. D., Quinn, K., Li, Q., Carroll, R., Warsinske, H., Vallania, F., Chen, S., Carns, M. A., Aren, K., Sun, J., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30508-3 · Cited by 237 · cited 1×
“It has been recently shown that increased peripheral monocytes are associated with poor outcome in patients with fibrotic diseases.(30) We cannot provide related information and this is a limitation of our study.”
BackgroundStratton, R., Shiwen, X., Martini, G., Holmes, A., Leask, A., Haberberger, T., Martin, G. R., Black, C. M., & Abraham, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12020 · Cited by 232
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Okamoto, M., Hoshino, T., Kitasato, Y., Sakazaki, Y., Kawayama, T., Fujimoto, K., Ohshima, K., Shiraishi, H., Uchida, M., Ono, J., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00059810 · Cited by 226 · cited 1×
“Serum periostin levels are elevated in IPF patients and are correlated with disease progression.(53,54) In accordance with the above, we observed an increase of periostin in BALF of our BLM-challenged mice, a phenomenon attenuated by treprostinil administration.”
ResultUchida, M., Shiraishi, H., Ohta, S., Arima, K., Taniguchi, K., Suzuki, S., Okamoto, M., Ahlfeld, S. K., Ohshima, K., Kato, S., et al. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0115oc · Cited by 174 · cited 1×
“The former is supported by other studies demonstrating that in BLM-challenged lungs, deposition of periostin colocalized with fibrotic areas and that periostin genetic ablation reduced collagen deposition.(55) Moreover, periostin production by fibrocytes was proven instrumental in inducing myofibroblast differentiatio…”
ResultMolecular biomarkers in idiopathic pulmonary fibrosis
Ley, B., Brown, K. K., & Collard, H. R. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00014.2014 · Cited by 172
Zhou, W., Hashimoto, K., Goleniewska, K., O’Neal, J. F., Ji, S., Blackwell, T. S., FitzGerald, G. A., Egan, K. M., Geraci, M. W., & Peebles, R. S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.702 · Cited by 165
Role of Osteopontin in the Pathogenesis of Bleomycin-Induced Pulmonary Fibrosis
Takahashi, F., Takahashi, K., Okazaki, T., Maeda, K., Ienaga, H., Maeda, M., Kon, S., Uede, T., & Fukuchi, Y. (2001) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.24.3.4293 · Cited by 160
Prostaglandin E2 and the Pathogenesis of Pulmonary Fibrosis
Bozyk, P. D., & Moore, B. B. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0025rt · Cited by 152
Stratton, R., Rajkumar, V., Ponticos, M., Nichols, B., Shiwen, X., Black, C. M., Abraham, D. J., & Leask, A. (2002) · The FASEB Journal · doi:10.1096/fj.02-0204fje · Cited by 143
Angulo, C., Rauch, M. C., Droppelmann, A., Reyes, A. M., Slebe, J. C., Delgado-López, F., Guaiquil, V. H., Vera, J. C., & Concha, I. I. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19981101)71:2<189::aid-jcb5>3.0.co;2-r · Cited by 130
COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis
Lovgren, A. K., Jania, L. A., Hartney, J. M., Parsons, K. K., Audoly, L. P., FitzGerald, G. A., Tilley, S. L., & Koller, B. H. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00492.2005 · Cited by 128 · cited 2×
“Besides, studies on human fetal lung fibroblasts revealed that two PGI2 analogues were able to inhibit fibroblast migration,(9) and most importantly prostacyclin analogues protected COX-2 / mice from BLM-induced pulmonary fibrosis.(10) Prostaglandin E2 (PGE2) and TXA2 are both involved in lung fibrosis; inhibition of…”
BackgroundBetensley, A., Sharif, R., & Karamichos, D. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm6010002 · Cited by 119 · cited 1×
“60–70 year old males are affected.(3) Pulmonary hypertension (PH) is a frequent complication of IPF and other chronic lung diseases,(4) increasing the morbidity and mortality of such patients.”
BackgroundPeriostin regulates fibrocyte function to promote myofibroblast differentiation and lung fibrosis
Ashley, S. L., Wilke, C. A., Kim, K. K., & Moore, B. B. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.61 · Cited by 115 · cited 1×
“Moreover, periostin production by fibrocytes was proven instrumental in inducing myofibroblast differentiation.(56) Focusing further on the molecular mechanisms underlying beneficial effects of treprostinil, apart from affecting osteopontin and periostin levels, we have also found affected inflammatory signalling path…”
BackgroundRoflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury
Cortijo, J., Iranzo, A., Milara, X., Mata, M., Cerdá‐Nicolás, M., Ruiz‐Saurí, A., Tenor, H., Hatzelmann, A., & Morcillo, E. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00041.x · Cited by 114 · cited 1×
“BLM has already been shown to induce pulmonary vascular remodeling.(22) Accordingly, in our study, BLM increased vascular muscularization, a phenomenon attenuated by treprostinil.”
BackgroundYang, J. H., Li, X., Al‐Lamki, R. S., Southwood, M. R., Zhao, J., Lever, A. M. L., Grimminger, F., SCHERMULY, R. T., & Morrell, N. W. (2010) · Circulation Research · doi:10.1161/circresaha.109.209940 · Cited by 102
Self-citationVancheri, C., Sortino, M. A., Tomaselli, V., Mastruzzo, C., Condorelli, F., Bellistrı́, G., Pistorio, M. P., Canonico, P. L., & Crimi, N. (2000) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.22.5.3948 · Cited by 97
Murao, Y., Loomis, W. H., Wolf, P. L., Hoyt, D. B., & JUNGER, W. G. (2003) · Shock · doi:10.1097/01.shk.0000071060.78689.f1 · Cited by 95
Zhang, W., Chen, G., Ren, J., & Zhao, Y. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12355 · Cited by 94 · cited 1×
“Other published results revealed that PGI2 analogues could also protect from pulmonary dysfunction by preserving endothelial barrier integrity; these effects involved IkBa degradation, as well as MAP kinase activity.(31) Overall, it appears that in BLM-induced fibrosis studied here, apart from exerting anti-fibrotic e…”
ResultProstaglandin E2protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction
Dackor, R. T., Cheng, J., Voltz, J. W., Card, J. W., Ferguson, C. D., Garrett, R. C., Bradbury, J. A., DeGraff, L. M., Lih, F. B., Tomer, K. B., et al. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00176.2011 · Cited by 90
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis
Fujimoto, H., Kobayashi, T., & Azuma, A. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23321 · Cited by 88 · cited 1×
“Idiopathic pulmonary fibrosis (IPF) is a chronic, fatal lung disease of unknown etiology with a median survival of patients not exceeding three to five years from diagnosis.(1,2) The result of progressive lung structure disruption is functional impairment and subsequently excessive morbidity and mortality.”
BackgroundA prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice
Zhu, Y.-J., Liu, Y., Zhou, W., Xiang, R., Jiang, L., Huang, K., Xiao, Y. P., Guo, Z., & Gao, J. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-34 · Cited by 78
Static and dynamic mechanics of the murine lung after intratracheal bleomycin
Manali, E. D., Moschos, C., Triantafillidou, C., Kotanidou, A. N., Psallidas, I., Karabela, S. P., Roussos, C., Papiris, S. A., Armaganidis, A., Stathopoulos, G. T., et al. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-33 · Cited by 73 · cited 1×
“The Cst of the respiratory system was then evaluated using data by three quasi-static PV curves, and more specifically by fitting of the Salazar–Knowles equation to the expiratory part of the loop.(18)”
MethodSelf-citationA Novel IκB Kinase-β Inhibitor Ameliorates Bleomycin-induced Pulmonary Fibrosis in Mice
Inayama, M., Nishioka, Y., Azuma, M., Muto, S., Aono, Y., Makino, H., Tani, K., Uehara, H., Izumi, K., Itai, A., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200506-947oc · Cited by 69
Choung, J., Taylor, L., Thomas, K. M., Zhou, X. C., Kagan, H. M., Yang, X., & POLGAR, P. R. (1998) · PubMed · Cited by 68
Murakami, S., Nagaya, N., Itoh, T., Kataoka, M., Iwase, T., Horio, T., Miyahara, Y., Sakai, Y., Kangawa, K., & Kimura, H. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00042.2005 · Cited by 67
High plasma concentrations of osteopontin in patients with interstitial pneumonia
Kadota, J., Mizunoe, S., Mito, K., Mukae, H., Yoshioka, S., Kawakami, K., Koguchi, Y., Fukushima, K., Kon, S., Kohno, S., et al. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.04.018 · Cited by 64 · cited 1×
“OPN is highly upregulated in IPF lungs,(47) in BALF of IPF patients and in serum of interstitial lung disease (ILD) patients when compared with controls.(48) We observed increased levels of OPN in mouse BALF due to BLM exposure and our finding is consistent with previous studies on experimental lung fibrosis.”
ResultIloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury
Birukova, A. A., Wu, T., Tian, Y., Meliton, A. Y., Sarich, N. A., Tian, X., Leff, A. R., & Birukov, K. G. (2012) · European Respiratory Journal · doi:10.1183/09031936.00148311 · Cited by 64
Self-citationRaychaudhuri, B., Malur, A., Bonfield, T. L., Abraham, S., Schilz, R. J., Farver, C. F., Kavuru, M. S., Arroliga, A. C., & Thomassen, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203567200 · Cited by 55
Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension
Dahal, B. K., Kosanovic, D., Pamarthi, P. K., Sydykov, A. S., Lai, Y., Kast, R., Schirok, H., Stasch, J.-P., Ghofrani, H. A., Weißmann, N., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00140309 · Cited by 51 · cited 1×
“Morphometry was performed as previously described.(20) Small vessels from 20 to 70 mm in diameter were counted and characterized blindly as fully muscularized (>75% a-SMA staining), partially muscularized (up to 75%) or non-muscularized.”
MethodSelf-citationCorboz, M. R., Zhang, J., LaSala, D., DiPetrillo, K., Li, Z., Malinin, V., Brower, J., Kuehl, P. J., Barrett, T. E., Perkins, W. R., et al. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.01.012 · Cited by 48 · cited 1×
“Finally and more recently an inhaled treprostinil prodrug was shown to attenuate collagen deposition in lungs of BLM-treated rats.(45) As diagnosis and prognosis of IPF remain extremely challenging,(1) several molecules have been proposed as possible markers, underlying the need to monitor disease presence and/or prog…”
BackgroundNikam, V. S., SCHERMULY, R. T., Dumitrascu, R., Weißmann, N., Kwapiszewska, G., Morrell, N. W., Klepetko, W., Fink, L., Seeger, W., & Voswinckel, R. (2010) · European Respiratory Journal · doi:10.1183/09031936.00028009 · Cited by 46 · cited 5×
“The latter implies that TREP might also attenuate the PH observed in patients with pulmonary fibrosis, since pulmonary vascular remodeling has a central role in the development of PH.”
BackgroundInfluentialSelf-citationKoh, S., Choi, Y., Kim, B. G., Lee, K. L., Kim, D. W., Kim, J. H., Kim, J. S., & Kim, J. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149652 · Cited by 46
Prostacyclin analogs inhibit fibroblast migration
Kohyama, T., Liu, X., Kim, H. J., Kobayashi, T., Ertl, R. F., Wen, F., Takizawa, H., & Rennard, S. I. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00432.2001 · Cited by 44
Cruz-Gervis, R., Stecenko, A. A., Dworski, R., Lane, K. B., Loyd, J. E., Pierson, R., King, G., & Brigham, K. L. (2002) · Respiratory Research · doi:10.1186/rr166 · Cited by 38 · cited 1×
“In human fibroblasts from IPF patients, the ratio of PGI2 to profibrotic thromboxane A2 (TXA2) was found lower compared to healthy lung fibroblasts, suggesting a trend towards fibrogenesis.(8) Besides, studies on human fetal lung fibroblasts revealed that two PGI2 analogues were able to inhibit fibroblast migration,(9…”
ResultProstaglandin D2 Attenuates Bleomycin-Induced Lung Inflammation and Pulmonary Fibrosis
Kida, T., Ayabe, S., Omori, K., Nakamura, T., Maehara, T., Aritake, K., Urade, Y., & Murata, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167729 · Cited by 32
Manitsopoulos, N., Nikitopoulou, I., Maniatis, N. A., Μagkou, C., Kotanidou, A. N., & Orfanos, S. E. (2017) · Respiration · doi:10.1159/000481201 · Cited by 25
Self-citationWang, W.-L., Kuo, C., Chu, Y. T., Huang, C.-H., Lam, K., Huang, S. K., Jong, Y. J., Kuo, Y.-T., & Hung, C. (2011) · Inflammation Research · doi:10.1007/s00011-011-0317-6 · Cited by 20
Τzouvelekis, Α., Tzilas, V., Papiris, S. A., Aidinis, V., & Bouros, D. E. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.12.002 · Cited by 20
Self-citationSerotonin 2B Receptor (5-HT2B R) Signals through Prostacyclin and PPAR-ß/δ in Osteoblasts
Chabbi-Achengli, Y., Launay, J., Maroteaux, L., de Vernejoul, M. C., & Collet, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075783 · Cited by 19
Zhou, W., Dowell, D. R., Geraci, M. W., Blackwell, T. S., Collins, R. D., Polosukhin, V. V., Lawson, W. E., Wu, P., Sussan, T. E., Biswal, S. S., et al. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00224.2010 · Cited by 16 · cited 1×
“11 Over-expression of PGI2 synthase attenuated inflammation in BLM-challenged mouse lungs without, though, reducing plasma protein leakage.(34) Overall, in vitro and in vivo studies have proven the barrier protective actions of prostacyclin analogues in different experimental models.”
BackgroundThe Effect of Tumor Necrosis Factor-?? on Microvascular Permeability in an Isolated, Perfused Lung
Schulman, C. I., Wright, J. K., Nwariaku, F. E., Sarosi, G., & Turnage, R. H. (2002) · Shock · doi:10.1097/00024382-200207000-00014 · Cited by 14
Revisiting prostacyclin: new directions in pulmonary fibrosis and inflammation
Soberman, R. J., & Christmas, P. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00102.2006 · Cited by 14 · cited 1×
“Prostacyclin (PGI2) elevates the levels of cyclic adenosine monophosphate (cAMP) and may thus control inflammation and fibrosis.(7) In human fibroblasts from IPF patients, the ratio of PGI2 to profibrotic thromboxane A2 (TXA2) was found lower compared to healthy lung fibroblasts, suggesting a trend towards fibrogenesi…”
BackgroundChandler, D., Giri, S. N., Chen, Z., & Hyde, D. M. (1983) · Prostaglandins Leukotrienes and Medicine · doi:10.1016/0262-1746(83)90105-1 · Cited by 11
Buckley, M. S., Berry, A., Kazem, N., Patel, S. A., & Librodo, P. (2014) · Core evidence · doi:10.2147/ce.s50607 · Cited by 11 · cited 1×
“intravenous or subcutaneous) that could cause discomfort and side-effects.(25,26) Exposure to BLM causes acute excessive cell accumulation, edema formation and, in later stages, ECM deposition and distorted lung architecture.”
BackgroundMirza, S., & Foley, R. J. (2012) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s8678 · Cited by 6 · cited 1×
“intravenous or subcutaneous) that could cause discomfort and side-effects.(25,26) Exposure to BLM causes acute excessive cell accumulation, edema formation and, in later stages, ECM deposition and distorted lung architecture.”
BackgroundDani, C., Pavoni, V., Corsini, I., Longini, M., Gori, G., Gianesello, L., Perna, A. M., Gritti, G., Paternostro, F., Forestieri, A., et al. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20695 · Cited by 6 · cited 1×
“Our results are supported by previous findings reporting the effects of inhaled PGI2 on lowering airway resistance and improving lung compliance in a PH model.(27) Additionally, another PGI2 analogue was recently shown to maintain lung function in BLM-challenged mice(28) and COX2-derived prostacyclin managed to preven…”
Result
Research works printed but not linked: 1
- Manitsopoulos N Kotanidou A Magkou C, et al. Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice. [abstract]. Eur Resp J 2015; 46: PA3837. PMC6883672 31819797
Cited by
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00165-x · Cited by 152
Li, X., Zhu, L., Wang, B., Yuan, M., & Zhu, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00855 · Cited by 108
The vascular perspective on acute and chronic lung disease
Borek, I., Birnhuber, A., Voelkel, N. F., Marsh, L. M., & Kwapiszewska, G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170502 · Cited by 103
“GK is a speaker for the Austrian Science Fund (FWF) DOC from direct improvements in the vascular compartment that occur as a consequence of inhibition of parenchymal fibroblast proliferation or from modulation of the local inflammatory milleu (174, 175).”
Group 3 Pulmonary Hypertension: From Bench to Bedside
Singh, N., Dorfmüller, P., Shlobin, O. A., & Ventetuolo, C. E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319970 · Cited by 98
Nathan, S. D., Behr, J., Cottin, V., Lancaster, L., Smith, P., Deng, C., Pearce, N., Bell, H., Peterson, L., & Flaherty, K. R. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001310 · Cited by 73
Metadata
- Authors
- Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., & Orfanos, S. E.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- GP Livanos and M Simou Laboratories 1st Department of Critical Care & Pulmonary Services Medical School National & Kapodistrian University of Athens Evangelismos Hospital Athens Greece
- Universities of Giessen and Marburg Lung Center Member of the German Center for Lung Research (DZL) Justus‐Liebig University Giessen Germany
- Justus-Liebig-Universität Gießen (DE)
- Department of Pathology Evangelismos Hospital Athens Greece
- Alexander Fleming Biomedical Sciences Research Center (GR)
- Sechenov University (RU)
- Corresponding author
- Orfanos, Stylianos E.
- Venue
- Pulmonary Circulation
- Publisher
- Wiley
- Published
- 2019-10
- Volume
- 9
- Issue
- 4
- Pages
- 1-14
- ISSN
- 2045-8932 (ISSN-L)
- 2045-8940
- PMC
- PMC6883672
- OpenAlex
- W2976822390
- Cited by
- 44
- References
- 62
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 5 · 2019: 1
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor, 31 d)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Pulmonary Circulation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- United Therapeutics Corporation (TRE-NC-004)
- Galenica-Ferrer (1348/2015)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- treprostinil, prostacyclin analogues, pulmonary fibrosis, bleomycin-induced lung injury, vascular remodeling, pulmonary hypertension, NF-κB signaling, lung inflammation, collagen deposition, VE-cadherin, bronchoalveolar lavage fluid, lung mechanics, prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.